Cabozantinib Tops Everolimus in Advanced RCC, Regardless of MET Expression

Expression of MET as measured by immunohistochemistry was not associated with any difference in the performance of cabozantinib as compared with everolimus in patients with advanced renal cell carcinoma.

Source: CancerNetwork - November 5, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Conferences/IKCS 2016 Kidney Cancer News Source Type: news